During the workshop we work with use cases that pharma organisations will recognise: concrete situations on which to run the legal, technical, validation and operational analysis. Participants discover for themselves where the line falls between a useful assistant and a high-risk system that could influence a batch block or patient exposure.
A first classic is cold chain anomaly detection. A pharma 3PL continuously receives IoT feeds from reefer containers, lorries, depot locations and distribution fridges. An AI model can spot patterns that precede an excursion (a combination of outside temperature, vehicle load, route segment, door openings and gateway latency) which individual threshold rules do not catch. The value does not lie in a replacement alarm system; that remains the validated data logger. The value lies in a second signal layer that lets your QA and operations teams act earlier, and in a retrospective tool that speeds up root cause analysis after an excursion. For the broader supply chain context, see our sister page on transport.
A second is route planning for EU pharma corridors. The major flows (Schiphol to Frankfurt, Rotterdam to Basel, Eindhoven to Mainz, Belgian border corridors) have fixed bottlenecks: border handling with third countries since Brexit, terminal turnaround times, weather-sensitive mountain passes and customs handovers. AI models that combine historical ETAs, weather data and previous excursion logs can suggest routes with a statistically lower temperature risk, as a supporting signal alongside QA's validated shipping lane choice.
A third is batch recall impact analysis. In a recall, the question is where a particular batch ended up and how quickly it was distributed. AI can help quickly aggregate serialisation events (verifier scans, release events, return flows) into an operational picture: which pharmacies, which wholesale depots and which patient populations are affected. We cover which architecture makes that analysis possible and which privacy limits apply.
A fourth is inventory forecasting with serialisation and shelf life. Unlike in non-pharma, this is not just about FIFO but about FEFO (First Expired, First Out), combined with batch status (released, blocked, quarantined), MAH instructions and, for clinical research, sponsor protocols. AI forecasts must handle these additional dimensions, otherwise they steer towards a reality that does not exist.
A fifth is disruption forecasting for port and border issues. Strikes, terminal outages, sanctions changes and extreme weather disrupt pharma flows especially hard, because rerouting without a validated route is not an option. AI can combine signals from news, terminal publications, AIS data and historical disruptions into an early warning, provided the signal is not mistaken for an operational instruction.
A sixth is audit trail completion and deviation assistance. An Annex 11 or GDP audit requires traceability of changes, deviations and CAPA steps, often scattered across the eQMS, email and spreadsheets. AI can help compile draft narratives that QA then reviews and validates. We cover where that is a responsible form of support and where it becomes dangerous, namely where AI could paper over a gap in the audit trail.
These cases serve as analysis material. We work through each one in terms of AI Act classification, GDP and Annex 11 position, data quality and practical feasibility within your stack. By the end, your team has a shared view of what is sensible to investigate first — and what is not (yet).